Allogene Therapeutics

Yahoo Finance • 10 hours ago

Allogene Prices $175 Mln Offering At $2 Per Share; Stock Down

(RTTNews) - Allogene Therapeutics, Inc. (ALLO) priced the previously announced $175 million public offering of 87.50 million shares at $2.00 per share. The offering is expected to close on or about April 16, 2026. Also, Allogene has grant... Full story

Yahoo Finance • 14 hours ago

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common stock at a price to the public o... Full story

Yahoo Finance • yesterday

Allogene Announces $175 Mln Public Offering

(RTTNews) - Allogene Therapeutics Inc. (ALLO), a clinical-stage biotechnology company, on Monday, announced a proposed underwritten public offering of $175 million in shares of the company's common stock. The proceeds from the public offe... Full story

Yahoo Finance • 3 days ago

Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) secured a spot on our list of the best penny stocks set to explode.Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)? As of April 8, 2026, analyst sentiment toward Allogene Therape... Full story

Yahoo Finance • 17 days ago

Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the penny stocks with potential to rise 1000 percent. Allogene Therapeutics said on March 12, 2026, that its lead program, cemacabtagene ansegedleucel, or cema-cel, remains on track in t... Full story

Yahoo Finance • last month

Allogene (ALLO) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, March 12, 2026 at 5 p.m. ET CALL PARTICIPANTS Chief Executive Officer — David ChangChief Medical Officer — Zachary RobertsChief Financial Officer — Geoffrey Parker Need a quote from a Motl... Full story

Yahoo Finance • 2 months ago

Atomera Among 3 Promising Penny Stocks

As February begins, major U.S. stock indexes have shown a robust start with the Dow Jones Industrial Average gaining 515 points and the S&P 500 nearing record highs. In such a buoyant market environment, investors often seek opportunities... Full story

Yahoo Finance • 4 months ago

What a Billionaire Family Office's $16.6 Million Exit From TIC Solutions Signals for Long-Term Investors

Key Points New York City-based Wildcat Capital Management sold 1.5 million shares of TIC in the third quarter. The shares were worth an estimated $16.56 million. The move marked a full exit from TIC, with the stake previously accounting... Full story

Yahoo Finance • 4 months ago

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to... Full story

Yahoo Finance • 4 months ago

December 2025 Penny Stocks Worth Watching

As the U.S. stock market navigates a complex landscape with tech stocks under pressure and indices like the Dow Jones Industrial Average experiencing fluctuations, investors are increasingly exploring diverse opportunities. Penny stocks, o... Full story

Yahoo Finance • 5 months ago

November 2025's Promising Penny Stocks To Watch

As the Dow Jones Industrial Average reaches an all-time high amid optimism over the potential end of a prolonged U.S. government shutdown, investors are keenly observing market dynamics and seeking opportunities across various sectors. Pen... Full story

Yahoo Finance • 5 months ago

Allogene signals pivotal ALPHA3 interim data and ALLO-329 proof-of-concept in first half 2026 while maintaining cash runway into H2 2027

Earnings Call Insights: Allogene Therapeutics (ALLO) Q3 2025 MANAGEMENT VIEW * CEO David Chang emphasized conviction in the company’s allogeneic platform, stating the focus is on “delivering what patients need now” and making “the prom... Full story

Yahoo Finance • 5 months ago

Here are the major earnings after the close Thursday

Major earnings expected after the bell on Thursday include: * Block (XYZ [https://seekingalpha.com/symbol/XYZ]) * The Trade Desk (TTD [https://seekingalpha.com/symbol/TTD]) * Airbnb (ABNB [https://seekingalpha.com/symbol/ABNB]) *... Full story

Yahoo Finance • 5 months ago

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimm... Full story

Yahoo Finance • 6 months ago

Allogene Therapeutics Faces Patent Infringement Challenges

Allogene Therapeutics (ALLO) said Tuesday that Factor Bioscience's patent infringement lawsuit again PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 months ago

Allogene licensor Cellectis faces patent lawsuit in the U.S.

[The Patent Application Process Important Paperwork and Necessary Tools for Success] Cancer drug developer Allogene Therapeutics (NASDAQ:ALLO [https://seekingalpha.com/symbol/ALLO]) announced on Tuesday that its licensor, Cellectis (NASDA... Full story

Yahoo Finance • 7 months ago

September 2025's Promising Penny Stocks Revealed

As U.S. markets navigate a rebound with the Nasdaq and S&P 500 rising, investors are keeping a close eye on potential government shutdowns and economic shifts. Amid these broader market movements, penny stocks continue to capture interest... Full story

Yahoo Finance • 8 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimm... Full story

Yahoo Finance • 8 months ago

Discover Promising Penny Stocks This August 2025

As of late August 2025, the U.S. stock market has shown resilience, with major indices closing higher despite political uncertainties and upcoming earnings reports from key players like Nvidia. In such a climate, investors often seek oppor... Full story

Yahoo Finance • 8 months ago

Allogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advances

Earnings Call Insights: Allogene Therapeutics (ALLO) Q2 2025 MANAGEMENT VIEW * CEO David D. Chang reported "significant advancement across our portfolio" and highlighted progress in three key programs: cema-cel in large B-cell lymphoma... Full story